Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

PURPOSE: The aim of this study was to improve the intratumoral accumulation of an antibody–drug conjugate (ADC) and minimize its off-target toxicity, SKB264, a novel anti-trophoblast antigen 2 (TROP2) ADC that was developed using 2-methylsulfonyl pyrimidine as the linker to conjugate its payload (KL...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yezhe, Yuan, Xiaoxi, Tian, Qiang, Huang, Xiuying, Chen, Yang, Pu, Yuzhi, Long, Hu, Xu, Mingyu, Ji, Yafei, Xie, Jia, Tan, Yuping, Zhao, Xi, Song, Hongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817100/
https://www.ncbi.nlm.nih.gov/pubmed/36620535
http://dx.doi.org/10.3389/fonc.2022.951589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817100/
https://www.ncbi.nlm.nih.gov/pubmed/36620535
http://dx.doi.org/10.3389/fonc.2022.951589

Ejemplares similares